[Intraperitoneal administration of beta-interferon in gastric cancer patients with peritoneal recurrence (ascites and serum IFN levels and its antitumor effect)].
D002288:Adenocarcinoma, Mucinous / Q000378:metabolism / Q000556:secondary / Q000628:therapy*; D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000378:metabolism*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000097:blood; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000378:metabolism / Q000556:secondary / Q000628:therapy*; D013274:Stomach Neoplasms
D007370:Interferon Type I